Atherosclerosis · Nov 2026

Lipoprotein(a) and incident peripheral artery disease in the Atherosclerosis Risk in Communities Study

By Lema K, Stapp EK, Kou M et al.

Background and Aims Lipoprotein(a) [Lp(a)] is an atherogenic, prothrombotic lipoprotein linked to atherosclerotic cardiovascular disease, but prospective data on its association with peripheral artery disease (PAD) in large, diverse U.S. cohorts are limited. We characterized the association of Lp(a) with long-term incident PAD risk in a diverse, community-based U.S. cohort. Methods We included Atherosclerosis Risk in Communities (ARIC) Study participants attending Visit 4 (1996–98) with measured Lp(a) and no prevalent PAD. Lp(a) was natural logarithm (ln)-transformed and categorized as <30, 30–50, and >50 mg/dL. Incident PAD was identified from hospitalization and procedure codes through 2019. Hazard ratios (HRs) were estimated using Cox models adjusted for confounders; Fine-Gray models and cumulative incidence functions accounted for competing mortality. Results Among 9,727 participants (mean age 63.1 years, 53.9% women, 20.4% Black), 825 incident PAD events occurred over a median 22.5 years of follow-up. Lp(a) was <30 mg/dL in 69.7%, 30–50 in 11.7%, and >50 in 18.6%. Fully adjusted HRs were 1.27 (95% confidence interval [CI], 1.03–1.57) for 30–50 mg/dL and 1.32 (95% CI, 1.11–1.57) for >50 mg/dL versus <30 mg/dL; each unit increase in ln(Lp(a)) was associated with an HR of 1.14 (95% CI, 1.07–1.20). Estimates were similar accounting for competing mortality, and cumulative incidence differed across categories (p < 0.001). The association did not differ by baseline statin use. Conclusions Higher Lp(a) was independently associated with greater long-term PAD risk in a community-based cohort, supporting Lp(a) as a risk factor for lower-extremity atherosclerotic disease and its value for risk stratification.

doi.org/10.1016/j.atherosclerosis.2026.121962Biomarkers

AgingResearch.News